Linklaters advises eureKING, the first european Special Purpose Acquisition Company (SPAC) dedicated to bioproduction, on its listing on Euronext Paris

Linklaters has advised eureKING, a SPAC sponsored by seven founders specialised in healthcare, including former general manager of Panasonic Healthcare Michael Kloss and former general manager of Sanofi-Aventis Gérard Le Fur, on its incorporation on the professional segment of Euronext Paris. 

eureKING is supported by the investment company eureKARE SA, focused on synthetic biology,  microbiome, and the development of a European network of AI-backed biotech studios.

The offer amounts is € 150 million, due to take place from the 9th to the 10th of May.

eureKING intends to invest in and acquire companies specialized in the production and manufacturing of biopharmaceutical products for other companies in the healthcare industry mainly in Europe.

eureKING is the first French SPAC to offer to its investors a redemption premium and is also the first SPAC in France to include a transfer of shares, subject to an earn-out clause, from its main shareholder to cornestone investors.

The Linklaters team that has advised eureKING was composed for incorporation matters of Bertrand Sénéchal, partner, Luis Roth, managing associate, Camille Rivet, associate, Romain Rihouey and Félix Laval-Sebire; on corporate matters, Zaid Bensebaa and Delphine Monnier, associates; on social law Géric Clomes, partner, Cécile Boulé and Netanel Taid Kashani, associates; on regulatory matters Laurent Benoit, counsel, and Jihane Guyot, managing associate; on intellectuel property matters Pauline Debré, partner, Jean-François Merdrignac, managing associate, and Raphaëlle Mottet, associate; on tax matters Cyril Boussion, partner, and Nadine Eng, managing associate.

Allen & Overy, with Olivier Thébault, Jade Billere-Mellet and Diana Billik, advised J.P. Morgan and Société Générale, acting as joint global coordinators and joint bookrunners.